{"transactions":[{"id":713049,"issuer":{"id":6537,"kind":"organization","name":"KAZIA THERAPEUTICS LTD"},"owners":[{"id":31502,"kind":"person","name":"Cain David","position":1,"cik":"0002125950","reported_name":"Cain David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Director, CMC"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-07-08T20:57:45.000Z","date":"2026-01-08","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a board-approved award of 100,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $9.10 per ADS. The exercise price for Australian resident participants reflects Australian tax considerations applicable to grants under the Issuer's employee share plan. One-third of the options vest on January 8, 2027 (the \"Commencement Date\") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. The options were granted for no consideration and expire on January 8, 2029."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents a board-approved award of 100,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $9.10 per ADS. The exercise price for Australian resident participants reflects Australian tax considerations applicable to grants under the Issuer's employee share plan. One-third of the options vest on January 8, 2027 (the \"Commencement Date\") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. The options were granted for no consideration and expire on January 8, 2029."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents a board-approved award of 100,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $9.10 per ADS. The exercise price for Australian resident participants reflects Australian tax considerations applicable to grants under the Issuer's employee share plan. One-third of the options vest on January 8, 2027 (the \"Commencement Date\") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. The options were granted for no consideration and expire on January 8, 2029."}],"balance_after":100000,"derivative":{"exercise_price":9.1,"underlying":"ADSs","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001213900-26-076427","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1075880/000121390026076427/ownership.xml","form_type":"4"}}]}